Pemvidutide
Dual GLP-1 and glucagon receptor agonist in clinical development. Studied for weight loss with notable lean muscle mass preservation through glucagon receptor-mediated mechanisms.
0 anonymous reports
Also known as:
ald-53glp-1 glucagon pemvidutide
browse topics:
community guides:
No reports found.
Community Q&A
- What makes pemvidutide different from other GLP-1 drugs?
- Community accounts describe pemvidutide's key differentiator as lean muscle mass preservation during weight loss — a property attributed to its glucagon receptor component. GLP-1-only accounts frequently describe muscle loss concerns during rapid weight reduction; pemvidutide accounts cite the preserved lean mass data as the primary reason for interest. The tradeoff described: pemvidutide is still in development, making sourcing and protocol guidance sparse compared to established agents.
- What are the side effects of pemvidutide?
- Community accounts are limited given the compound's development stage. Where side effects are described, the profile mirrors other dual agonists: GI adjustment in the first weeks (nausea, reduced appetite), with accounts noting somewhat less severe nausea than pure GLP-1 agents. The glucagon component in confessions is associated with more noticeable energy expenditure effects — feeling warmer and higher resting energy expenditure described more than with semaglutide.